Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Early Breast Cancer
NCT01861054Phase 2Terminated
- Sponsor
- Dompé
- Start
- Feb 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reparixin in breast cancer, sponsored by Dompé. Primary endpoints: Change From Baseline to Day 21 in Markers of Cancer Stem Cells (CSCs) in the Primary Tumor and the Tumoral Microenvironment, Change From Baseline-1 to Day 21-1 in Pathway Markers by IHC and 4 more. Started Feb 2013; status: terminated.
02
Drugs
reparixin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01861054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861054.